Standard
Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). / Jensen, Jesper; Omar, Massar; Kistorp, Caroline; Tuxen, Christian; Gustafsson, Ida; Køber, Lars; Gustafsson, Finn; Faber, Jens; Forman, Julie L.; Møller, Jacob E.; Schou, Morten.
I:
Circulation, Bind 143, Nr. 22, 2021, s. 2208-2210.
Publikation: Bidrag til tidsskrift › Letter › Forskning › fagfællebedømt
Harvard
Jensen, J, Omar, M
, Kistorp, C, Tuxen, C, Gustafsson, I
, Køber, L, Gustafsson, F, Faber, J, Forman, JL, Møller, JE
& Schou, M 2021, '
Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)',
Circulation, bind 143, nr. 22, s. 2208-2210.
https://doi.org/10.1161/CIRCULATIONAHA.120.053463APA
Jensen, J., Omar, M.
, Kistorp, C., Tuxen, C., Gustafsson, I.
, Køber, L., Gustafsson, F., Faber, J., Forman, J. L., Møller, J. E.
, & Schou, M. (2021).
Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).
Circulation,
143(22), 2208-2210.
https://doi.org/10.1161/CIRCULATIONAHA.120.053463Vancouver
Jensen J, Omar M
, Kistorp C, Tuxen C, Gustafsson I
, Køber L o.a.
Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic).
Circulation. 2021;143(22):2208-2210.
https://doi.org/10.1161/CIRCULATIONAHA.120.053463Author
Jensen, Jesper ; Omar, Massar ; Kistorp, Caroline ; Tuxen, Christian ; Gustafsson, Ida ; Køber, Lars ; Gustafsson, Finn ; Faber, Jens ; Forman, Julie L. ; Møller, Jacob E. ; Schou, Morten. / Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic). I: Circulation. 2021 ; Bind 143, Nr. 22. s. 2208-2210.
Bibtex
@article{c0b2710db58f4f65aa96a2f5394763a3,
title = "Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)",
keywords = "body composition, diabetes mellitus, type 2, empagliflozin, heart failure, insulin resistance, sodium-glucose transporter 2 inhibitors, REDUCED EJECTION FRACTION",
author = "Jesper Jensen and Massar Omar and Caroline Kistorp and Christian Tuxen and Ida Gustafsson and Lars K{\o}ber and Finn Gustafsson and Jens Faber and Forman, {Julie L.} and M{\o}ller, {Jacob E.} and Morten Schou",
year = "2021",
doi = "10.1161/CIRCULATIONAHA.120.053463",
language = "English",
volume = "143",
pages = "2208--2210",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams & Wilkins",
number = "22",
}
RIS
TY - JOUR
T1 - Metabolic Effects of Empagliflozin in Heart Failure A Randomized, Double-Blind, and Placebo-Controlled Trial (Empire HF Metabolic)
AU - Jensen, Jesper
AU - Omar, Massar
AU - Kistorp, Caroline
AU - Tuxen, Christian
AU - Gustafsson, Ida
AU - Køber, Lars
AU - Gustafsson, Finn
AU - Faber, Jens
AU - Forman, Julie L.
AU - Møller, Jacob E.
AU - Schou, Morten
PY - 2021
Y1 - 2021
KW - body composition
KW - diabetes mellitus
KW - type 2
KW - empagliflozin
KW - heart failure
KW - insulin resistance
KW - sodium-glucose transporter 2 inhibitors
KW - REDUCED EJECTION FRACTION
U2 - 10.1161/CIRCULATIONAHA.120.053463
DO - 10.1161/CIRCULATIONAHA.120.053463
M3 - Letter
C2 - 34061581
VL - 143
SP - 2208
EP - 2210
JO - Circulation
JF - Circulation
SN - 0009-7322
IS - 22
ER -
